Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity
- PMID: 36068462
- DOI: 10.1007/978-1-0716-2573-6_5
Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity
Abstract
Pharmacogenomics is a powerful tool to predict individual response to treatment, in order to personalize therapy, and it has been explored extensively in oncology practice. Not only efficacy on the malignant disease has been investigated but also the possibility to predict adverse effects due to drug administration. Chemotherapy-induced peripheral neurotoxicity (CIPN) is one of those. This potentially severe and long-lasting/permanent side effect of commonly administered anticancer drugs can severely impair quality of life (QoL) in a large cohort of long survival patients. So far, a pharmacogenomics-based approach in CIPN regard has been quite delusive, making a methodological improvement warranted in this field of interest: even the most refined genetic analysis cannot be effective if not applied correctly. Here we try to devise why it is so, suggesting how THE "bench-side" (pharmacogenomics) might benefit from and should cooperate with THE "bed-side" (clinimetrics), in order to make genetic profiling effective if applied to CIPN.
Keywords: Chemotherapy-induced peripheral neurotoxicity; Personalized medicine; Pharmacogenomics.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Management of side effects in the personalized medicine era: chemotherapy-induced peripheral neuropathy.Methods Mol Biol. 2014;1175:301-22. doi: 10.1007/978-1-4939-0956-8_12. Methods Mol Biol. 2014. PMID: 25150874 Review.
-
Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.J Natl Cancer Inst. 2014 Mar 12;106(5):dju044. doi: 10.1093/jnci/dju044. J Natl Cancer Inst. 2014. PMID: 24623533 Free PMC article. Review.
-
Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics.Nat Rev Neurol. 2017 Aug;13(8):492-504. doi: 10.1038/nrneurol.2017.88. Epub 2017 Jun 30. Nat Rev Neurol. 2017. PMID: 28664909 Review.
-
In vitro neurotoxicity testing: lessons from chemotherapy-induced peripheral neurotoxicity.Expert Opin Drug Metab Toxicol. 2024 Nov-Dec;20(11-12):1037-1052. doi: 10.1080/17425255.2024.2401584. Epub 2024 Sep 10. Expert Opin Drug Metab Toxicol. 2024. PMID: 39246127 Review.
-
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics.Lancet Oncol. 2011 Nov;12(12):1151-61. doi: 10.1016/S1470-2045(11)70131-0. Epub 2011 Jun 28. Lancet Oncol. 2011. PMID: 21719347 Review.
References
-
- Syvänen AC (2005) Toward genome-wide SNP genotyping. Nat Genet 37(Suppl):S5–S10 - PubMed
-
- Velasco R, Alberti P, Bruna J et al (2019) Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment. J Peripher Nerv Syst 24(Suppl 2):S52–S62 - PubMed
-
- Islam B, Lustberg M, Staff NP et al (2019) Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment. J Peripher Nerv Syst 24(Suppl 2):S63–S73 - PubMed
-
- Tamburin S, Park SB, Alberti P et al (2019) Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment. J Peripher Nerv Syst 24(Suppl 2):S40–S51 - PubMed
-
- Alberti P (2019) Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence. Expert Opin Drug Metab Toxicol 15(6):487–497 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical